Apollo Cancer Centres

Name

Apollo Cancer Centres

Legal name

Apollo Hospitals Enterprises Ltd.

Website

https://apollocancercentres.com

Company type

Public

Operating status

Operating

Headcount range

5,001–10,000 employees

Ownership category

akta.pro rank

Product category

Oncology Hospital Services

NAICS

Specialty (except Psychiatric and Substance Abuse) Hospitals (62231)

SIC

Services-Hospitals (8060), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Oncology & Cancer Specialty Hospitals (HLAFAHAC)

akta.pro secondary industries

Ambulatory Oncology Centers (Outpatient Chemo/Radiation) (HLAFABAI), Medical Oncology (HLAKAFAB), Surgical Oncology (HLAKAFAG), Gastrointestinal Oncology (HLAKAFAK), Oncology & Specialty Treatment Travel Agencies (THAKAIAI)

Keywords

• Cancer treatment services
• Oncology hospital network
• Radiation oncology services
• Surgical oncology treatments
• Cancer diagnostic imaging

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices18 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Infrastructure, Operations, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Diagnostic Services: Revenue from laboratory services (biochemistry, microbiology, pathology including digital and molecular pathology), imaging services (PET-CT, CT, MRI, mammography, ultrasound), and specialized diagnostics (PSMA PET-CT, colonoscopy, endoscopy).
2. Medical Oncology Treatments: Revenue from chemotherapy, immunotherapy, targeted therapy, and CAR-T cell therapy treatments administered to inpatients and outpatients.
3. Radiation Oncology Services: Revenue from radiation treatments including proton therapy, CyberKnife, stereotactic radiosurgery, IGRT, IMRT, brachytherapy, and 3D conformal radiation therapy.
4. Surgical Oncology: Revenue from surgical procedures including robotic onco surgery, HIPEC, PIPAC, minimally invasive surgery, and limb salvage surgery.
5. Bone Marrow Transplantation: Revenue from BMT procedures, with support programs for economically weaker patients through partnerships.
6. Consultation Services: Revenue from specialist consultations across multiple oncologist specialties including haematology, medical, radiation, nuclear medicine, and surgical oncology.
7. International Patient Services: Dedicated services for international patients including coordination, accommodation assistance, and treatment planning.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Apollo Cancer Centres operates a network of 22+ dedicated tertiary cancer hospitals across India delivering comprehensive oncology services including advanced diagnostics (PET-CT, molecular pathology), medical oncology (chemotherapy, immunotherapy, targeted therapy, CAR-T cell therapy), radiation oncology (proton therapy, CyberKnife, IGRT/IMRT/SBRT/SRS, brachytherapy), surgical oncology (robotic onco surgery, HIPEC, PIPAC, minimally invasive surgery), theranostics, and bone marrow transplantation. The network also runs rapid diagnosis campaigns, hereditary risk assessment, survivorship programs, and international patient services.

Product overview

Apollo Cancer Centres (ACCs) operates as a comprehensive cancer care platform with multiple treatment centers across India (Ahmedabad, Bangalore, Bhubaneshwar, Chennai, Delhi, Hyderabad, Kolkata, Lucknow, Mumbai, Pune, Vizag, and others). The portfolio includes diagnostic services (PET-CT, PSMA PET-CT, Digital Pathology, Molecular Pathology, radiology and imaging), medical treatments (Chemotherapy, Immunotherapy, Targeted Therapy, CAR T-Cell Therapy), radiation treatments (CyberKnife, Proton Therapy, Brachytherapy, IGRT, IMRT, SBRT, SRS), surgical treatments (Robotic Onco Surgery, HIPEC, PIPAC, Minimally Invasive Surgery, RFA), nuclear medicine (Theranostics), and support services (CANWIN Cancer Support Group, Apollo Pathshala). The center offers specialized rapid diagnosis campaigns for breast, lung, colon, oral, endometrial/ovarian, and stomach cancers. Recent innovations include the Check-Olate breast self-examination awareness initiative and PET-CT scanning services. Apollo Cancer Centres provides integrated care across 13 cancer types: Bone & Soft Tissue, Breast, Gastrointestinal, Gynaecological, Haematological, Head & Neck, Neurological, Ophthalmic, Paediatric, Skin Cancer, Thoracic, and Urological.

Differentiator

Problem solved

Functional benefit

Brands

• Check-Olate: A dark chocolate bar embedded with QR code linking to animated breast self-examination instructions, launched during Breast Cancer Awareness Month to normalize monthly breast self-examination among women.
• CANWIN

Products and services

• PET-CT Scan Advanced imaging technology that maps metabolic activity in tumor cells to detect malignancy with precision, often before anatomical changes appear on conventional scans, used for cancer staging and treatment response monitoring.
• Bone Marrow Transplantation (BMT) Curative treatment for Thalassemia Major and other haematological conditions; the only established curative treatment for Thalassemia Major, reducing dependence on lifelong blood transfusions, supported by charitable access programs for economically weaker patients.
• Robotic Onco Surgery Robot-assisted surgical procedures for enhanced precision in cancer treatment, including nipple-sparing mastectomy, complex ovarian surgeries with HIPEC, thyroid, and pancreatic surgeries, reducing recovery times and healthcare costs.
• CyberKnife Stereotactic Radiosurgery Robotic radiosurgery system for precise, non-invasive treatment of tumors and conditions throughout the body, used as a non-invasive alternative to surgical tumor removal.
• Proton Therapy Advanced radiation therapy using proton beams to target cancer cells with precision while minimizing damage to surrounding healthy tissue.
• CAR-T Cell Therapy Advanced immunotherapy that modifies a patient's own T cells to attack cancer cells, primarily used for blood cancers.
• HIPEC (Hyperthermic Intraperitoneal Chemotherapy) Combination treatment involving surgery and heated chemotherapy administered directly into the abdominal cavity during surgery for gastrointestinal and gynaecological cancers.
• Immunotherapy Cancer treatment that uses the body's immune system to identify and fight cancer cells.
• Targeted Therapy Cancer treatment using drugs or other substances to precisely identify and attack specific types of cancer cells based on molecular markers.
• Theranostics Combination of therapeutics and diagnostics using radioactive tracers for personalized cancer treatment within nuclear medicine.
• Chemotherapy Systemic cancer treatment using drugs to destroy cancer cells throughout the body, delivered across inpatient and outpatient settings.
• Brachytherapy Internal radiation therapy where radioactive sources are placed inside or near the tumor for localized high-dose treatment.
• Image-Guided Radiation Therapy (IGRT) Radiation therapy that uses imaging during treatment to precisely target tumors while minimizing damage to surrounding healthy tissue.
• Intensity Modulated Radiation Therapy (IMRT) Advanced radiation therapy that modulates the intensity of radiation beams to conform to the three-dimensional shape of the tumor.
• Stereotactic Body Radiotherapy (SBRT) Precise radiation therapy that delivers high doses of radiation to extracranial tumors in fewer treatment sessions.
• Stereotactic Radiosurgery (SRS) Non-invasive radiation surgery for brain and spine tumors using highly focused radiation beams delivered with sub-millimeter precision.
• PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy) Innovative approach to delivering chemotherapy directly into the abdominal cavity as a pressurized aerosol for peritoneal surface malignancies.
• Radiofrequency Ablation (RFA) Minimally invasive procedure using heat generated by radio waves to destroy cancer cells in solid tumors.
• Minimally Invasive Surgery Surgical techniques using small incisions and specialized instruments to enable faster recovery and reduced post-operative complications.
• Digital Pathology Digital imaging and analysis of tissue samples to enable accurate, scalable cancer diagnosis and remote pathologist review.
• Molecular Pathology Genetic and molecular testing for personalized cancer diagnosis and treatment planning, including biomarker identification for targeted therapies.
• PSMA PET-CT Specialized PET-CT imaging using prostate-specific membrane antigen (PSMA) tracers for prostate cancer detection and staging.
• International Patient Services Dedicated services for international cancer patients including treatment planning, travel coordination, visa support, and accommodation assistance.

Quantifiable outcome

• PET-CT imaging enables detection of malignancy before anatomical changes appear on conventional scans
• +2 more outcomes

Named customers1 record

Segments12 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Two partnerships are on record, tiered core.

• Coal India Ltd (Thalassemia Bal Sewa Yojana)coreStrategic or Co-development Partner · 14 May 2026Apollo Cancer Foundation and Apollo Speciality Hospitals participate in the Thalassemia Bal Sewa Yojana, implemented in partnership with Coal India Ltd. The program supports access to Bone Marrow Transplantation (BMT) for economically weaker children with Thalassemia Major. The partnership celebrated 30 thalassemia survivors on World Thalassemia Day 2026, reaffirming the commitment to improving access to BMT as the only established curative treatment for Thalassemia Major.
• Apollo Hospitals Enterprise LimitedcoreOthersApollo Cancer Centres operates as a specialized division of Apollo Hospitals Enterprise Limited, leveraging the parent company's network of hospitals, administrative infrastructure, and brand reputation across India.

Scale indicators4 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• HealthCare Global Enterprises (HCG): HCG is India's largest dedicated oncology hospital chain, operating ~20+ cancer centres across India. It is the closest pure-play oncology network peer to Apollo Cancer Centres, competing head-to-head on multi-modality cancer care across similar geographies and with comparable technology breadth.
• Tata Memorial Centre: Tata Memorial Hospital in Mumbai is India's premier government-supported cancer hospital, treating the largest volume of cancer patients in the country. It is a direct peer in comprehensive oncology services and sets the benchmark for clinical depth, even though it is publicly subsidised.
• City of Hope (formerly Cancer Treatment Centers of America): City of Hope is a US specialty cancer hospital and research centre offering multi-modality oncology care including CAR-T, proton therapy, and BMT. It is comparable to Apollo Cancer Centres as a dedicated, multi-modality oncology platform, although its scale, geography, and payer mix differ.
• Basavatarakam Indo American Cancer Hospital: Basavatarakam Indo American Cancer Hospital in Hyderabad is a leading not-for-profit dedicated cancer hospital in India. It is a direct peer as a specialty oncology hospital focused on comprehensive cancer care, competing with Apollo's Hyderabad centres for patient volume.

Broad incumbents

• Fortis Healthcare: Fortis operates a large multi-specialty hospital network in India with significant oncology programmes (including Fortis Memorial Research Institute in Gurgaon). It overlaps with Apollo Cancer Centres on cancer diagnostics, surgery, and medical/radiation oncology but offers these as part of a much wider hospital portfolio.
• Max Healthcare: Max Healthcare is a leading North India hospital chain with strong oncology offerings, including the Max Institute of Cancer Care. It competes with Apollo Cancer Centres for premium oncology patients in Delhi NCR and other metros, but oncology is part of a broader multi-specialty portfolio.
• Manipal Hospitals: Manipal Hospitals runs one of India's largest hospital networks with dedicated oncology programmes. It competes with Apollo Cancer Centres for cancer patients across South and West India but is primarily a general multi-specialty operator rather than a focused oncology chain.
• Medanta - The Medicity: Medanta operates large multi-super-specialty hospitals with a prominent Cancer Institute, offering surgical, medical, and radiation oncology. It is a competing tertiary-care provider to Apollo Cancer Centres in North India but is broader than a dedicated cancer hospital.
• Aster DM Healthcare: Aster DM operates hospitals and clinics across India and the GCC with oncology among its specialities. It is comparable as a large hospital network that includes cancer care but is not an oncology-focused chain.

Emerging players

• Cytecare Cancer Hospitals: Cytecare is an India-based dedicated cancer hospital chain offering multi-modality oncology care. It is a smaller, emerging specialty competitor compared to Apollo Cancer Centres' nationwide footprint but operates in a directly comparable oncology-focused model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@apollocancercentres
• Facebookfacebook.com/apollocancercentres
• LinkedInlinkedin.com/company/apollo-cancer-centres
• Instagraminstagram.com/apollocancercentres
• Xx.com/cancer_apollo

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Apollo Cancer Centres